BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The Meaning of Breaking the Pen's Nib in Death penalties - 2Foot fossil discovery could reshape human evolutionary history
- 3Israel issues notice that Ben-Gurion Airport flights likely restricted until at least April 16
- 4Staggering Spots to Stargaze All over the Planet
- 5The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- How many ships have been attacked in the Gulf since start of Iran war?
- This Unique National Park In Canada Is Famous For Its Otherworldly Limestone Monoliths
- Closets for Your Room: Plan and Utility Features
- Katz alleges Army Radio workers misled High Court in bid to halt closure
- Instructions to Upgrade the Security Elements of Your Kona SUV
- Joshua Made Last-Second Seat Change That Saved His Life
- Burkina Faso forces killed twice as many civilians as jihadists, rights group says
- A definitive Manual for Choosing Indoor Plants Ideal for Your Space
- Police break up illegal chicken slaughter in Germany
